Transthyretin Amyloid Cardiomyopathy (ATTR-CM) For Professionals

Eliminate the What-If. Learn When to Rule Out ATTR-CM.

When patients present with preserved ejection fraction and no clear cause, it’s time to consider Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The symptoms can be similar, but ATTR-CM has a different prognosis and requires unique management strategies.

Learn when to test and more about ATTR-CM on our podcast series.

portrait of senior man with cane

Hear from the Experts

Michelle M Kittleson

Michelle Kittleson, M.D., Ph.D.
  • Director of Heart Failure Research and Post-Graduate Education in Heart Failure and Transplantation
  • Associate Professor of Medicine at Smidt Heart Institute, Cedars-Sinai

Amrut V. Ambardekar, M.D.

Amrut V. Ambardekar, M.D.
  • Medical Director Cardiac Transplant Program
  • Associate Professor, Medicine-Cardiology University of Colorado

Richard Hawkins ATTR-CM Survivor

Richard Hawkins

ATTR-CM Survivor

ATTR-CM Expert Podcast Series

Learn when to test and even more about ATTR-CM on our podcast series.

Episode 1 - What is ATTR-CM?

Episode 2 - Causes and Symptoms of ATTR-CM

Episode 3 - Diagnosis and Treatment Options

What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. Read about the types of ATTR-CM, as well as the risk factors, symptoms, and treatment.
Heart Insight Summer 2019 cover

Heart Insight Summer 2019 Issue

ATTR-CM

Underdiagnosed Cause of HF